tiprankstipranks
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market

Summit Therapeutics (SMMT) Stock Price & Analysis

261 Followers

SMMT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.30 - $5.22
Previous Close$4.62
Volume9.77M
Average Volume (3M)2.13M
Market Cap
$3.33B
Enterprise Value$3.25B
Total Cash (Recent Filing)$186.24M
Total Debt (Recent Filing)$106.10M
Price to Earnings (P/E)-3.0
Beta-1.34
May 09, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding701,697,179
10 Day Avg. Volume2,864,428
30 Day Avg. Volume2,133,357
Standard Deviation0.61
R-Squared0.01
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)34.16
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.57K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

82.79%1.40%2.33%13.47%
82.79% Insiders
2.33% Other Institutional Investors
13.47% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

SMMT FAQ

What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $1.30 and its highest was $5.22 in the past 12 months.
    What is Summit Therapeutics’s market cap?
    Currently, no data Available
    When is Summit Therapeutics’s upcoming earnings report date?
    Summit Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 44 days.
      How were Summit Therapeutics’s earnings last quarter?
      Summit Therapeutics released its earnings results on Feb 20, 2024. The company reported -$0.052 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.052.
        Is Summit Therapeutics overvalued?
        According to Wall Street analysts Summit Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Summit Therapeutics pay dividends?
          Summit Therapeutics does not currently pay dividends.
          What is Summit Therapeutics’s EPS estimate?
          Summit Therapeutics’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Summit Therapeutics have?
          Summit Therapeutics has 701,697,200 shares outstanding.
            What happened to Summit Therapeutics’s price movement after its last earnings report?
            Summit Therapeutics reported an EPS of -$0.052 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -26.233%.
              Which hedge fund is a major shareholder of Summit Therapeutics?
              Among the largest hedge funds holding Summit Therapeutics’s share is Robert Bender&Associates. It holds Summit Therapeutics’s shares valued at 63K.
                ---

                Company Description

                Summit Therapeutics

                Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Gilead Sciences
                Vertex Pharmaceuticals
                BioMarin Pharmaceutical
                Incyte
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis